首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126416

失智症診斷市場－策略分析與預測（2026-2035）

Dementia Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計失智症診斷市場將從 2026 年的 98.9 億美元成長到 2035 年的 244.8 億美元，複合年成長率為 10.56%。

全球失智症診斷市場正經歷著一場根本性的變革，從基於症狀的評估轉向基於病理的診斷。這項轉變的驅動力在於疾病修正治療的日益普及，而這些療法越來越需要病理學確認來確定治療合格增加，對能夠區分各種類型失智症（例如阿茲海默症、血管性失智症和路易氏體失智症）的精準診斷解決方案的需求持續成長。全球監管機構正在推動基於生物標記的診斷方法的開發和檢驗，而醫療服務提供者則在投資於整合檢測、影像和人工智慧 (AI)觀察解讀的綜合診斷工作流程，以提高效率和臨床療效。這些結構性變化正在將失智症診斷確立為現代神經健康護理的重要組成部分。

市場促進因素

生物標記診斷的廣泛應用

客觀的生物標記評估正日益成為失智症診斷的核心，因為臨床醫生在啟動針對性治療策略之前需要病理學確診。血液來源生物標記和腦脊髓液檢測的日益普及降低了診斷的不確定性，同時提高了區分阿茲海默症與其他失智症亞型的能力。臨床檢查室正在擴大檢測能力以應對不斷成長的診斷數量，從而推動了對自動化分析平台的需求。診斷設備製造商正透過開發高靈敏度的生物標記檢測來滿足這項需求，這些檢測能夠提高分析性能和臨床應用率。

對神經退化性疾病早期檢測的需求日益成長

早期診斷使臨床醫生能夠在不可逆的神經損傷顯著加重之前進行治療性介入。疾病的早期識別有助於改善長期管理，因此醫療專業人員擴大對輕度認知障礙患者篩檢。由於傳統的基於症狀的診斷往往會延遲干預，因此人們對能夠檢測臨床前病理變化的更靈敏的診斷技術的需求日益成長。技術開發人員正在擴展其在影像學和分子診斷方面的能力，以提高早期疾病檢測的準確性，從而推動了醫院和專科神經科中心對先進解決方案的需求。

將人工智慧（AI）整合到診斷工作流程中

人工智慧 (AI) 透過輔助自動分析神經影像數據，識別人工檢查中可能被忽略的細微病理模式，從而提高診斷效率。由於許多地區的神經科數量仍然有限，醫療機構正在採用人工智慧驅動的決策支援系統。隨著診斷變得越來越複雜，需要擴充性的分析工具，以便在不同的臨床環境中保持一致性。技術供應商正在將機器學習演算法與影像診斷平台和數位認知功能評估系統整合，以簡化診斷工作流程，從而提高診斷準確性和營運效率。

神經病學精準醫療的擴展

精準醫療依賴準確的疾病分類，因為治療效果會因潛在的神經病理學而異。製藥公司正日益開發標靶治療，這些療法需要在開始治療前通過檢驗的診斷進行確認。因此，醫療機構需要能夠整合生物標記分析、神經影像學和臨床評估的綜合診斷流程。診斷設備製造商正在擴展其全面的檢測產品組合，以支援個人化治療方案的選擇，這推動了對先進診斷技術的持續需求。

市場限制因素

先進神經影像系統和專業生物標記檢測的高成本阻礙了其在資源匱乏的醫療機構中的廣泛應用。此外，訓練有素的神經科醫生、神經放射科醫生和專業技術人員數量有限，導致儘管患者需求不斷成長，診斷能力仍然不足。針對新型生物標記檢測和先進影像檢查的報銷政策差異，也減緩了這些技術在多個醫療市場的常規臨床應用。此外，將新的診斷技術整合到現有醫療基礎設施中的複雜性也帶來了營運方面的障礙。病患健康資訊的資料隱私和安全問題，也給診斷平台提供者帶來了合規方面的負擔。

依產品
- 神經影像系統
- 腦脊髓液（CSF）生物標記檢測
- 血液衍生生物標記檢測
- 基因檢測
- 認知功能評估工具
- 數位認知功能評估平台
透過診斷技術
- 磁振造影（MRI）
- 電腦斷層掃描（CT）
- 正子斷層掃描（PET）
- 生物標記診斷
- 分子診斷
- 基於人工智慧的診斷
失智症的類型
- 阿茲海默症
- 血管性失智症
- 路易氏體失智症
- 額顳葉型失智症
- 混合型失智症
- 其他類型的失智症

第10章：全球失智症診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球失智症診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
韓國
印度
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

Roche Diagnostics
Fujirebio Holdings, Inc.
Siemens Healthineers AG
GE HealthCare
Koninklijke Philips NV
Beckman Coulter, Inc.
Abbott Laboratories
Quanterix Corporation
Sysmex Corporation
C2N Diagnostics LLC
Bio-Techne Corporation
Lumipulse（Fujirebio）
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings（Labcorp）
PerkinElmer Inc.

第14章全球失智症診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009127

The Dementia Diagnostics Market is anticipated to grow at a CAGR of 10.56% from USD 9.89 billion in 2026 to USD 24.48 billion in 2035.

The global dementia diagnostics market is undergoing a fundamental transformation, shifting from symptom-driven evaluation toward pathology-based diagnosis. This transition is fueled by the growing availability of disease-modifying therapies, which increasingly require pathological confirmation for treatment eligibility. The market encompasses a range of technologies and services, including neuroimaging systems, cerebrospinal fluid (CSF) biomarker tests, blood-based biomarker tests, genetic testing, and cognitive assessment tools. Rising global life expectancy continues to expand the elderly population, creating sustained demand for accurate diagnostic solutions that can differentiate between various dementia types such as Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. Regulatory agencies worldwide are encouraging the development and validation of biomarker-driven diagnostics, while healthcare providers invest in integrated diagnostic workflows combining laboratory testing, imaging, and artificial intelligence-assisted interpretation to improve efficiency and clinical outcomes. These structural changes position dementia diagnostics as an essential component of modern neurological care.

Market Drivers

Increasing Adoption of Biomarker-Based Diagnosis

Objective biomarker assessment is becoming central to dementia diagnosis because clinicians require pathological confirmation before initiating targeted therapeutic strategies. The growing availability of blood-based biomarkers and cerebrospinal fluid assays is reducing diagnostic uncertainty while improving differentiation between Alzheimer's disease and other dementia subtypes. Clinical laboratories are expanding testing capabilities to support increasing diagnostic volumes, creating greater demand for automated analytical platforms. Diagnostic manufacturers are responding through development of highly sensitive biomarker assays that improve analytical performance and clinical adoption.

Growing Demand for Early Detection of Neurodegenerative Disorders

Earlier diagnosis enables clinicians to implement therapeutic interventions before irreversible neurological damage significantly progresses. Healthcare providers are increasingly screening individuals with mild cognitive impairment because earlier disease identification supports improved long-term management. Conventional symptom-based diagnosis often delays intervention, creating pressure for more sensitive diagnostic technologies capable of detecting preclinical pathological changes. Technology developers are expanding imaging and molecular diagnostic capabilities that improve detection during earlier disease stages, strengthening demand for advanced solutions across hospitals and specialized neurological centers.

Integration of Artificial Intelligence into Diagnostic Workflows

Artificial intelligence improves diagnostic efficiency by supporting automated interpretation of neuroimaging data and identifying subtle pathological patterns that may be overlooked during manual review. Healthcare facilities are incorporating AI-assisted decision support because neurological specialists remain limited in many regions. Increasing diagnostic complexity requires scalable analytical tools that maintain consistency across diverse clinical environments. Technology providers are integrating machine learning algorithms with imaging platforms and digital cognitive assessment systems to streamline diagnostic workflows, strengthening both accuracy and operational efficiency.

Expansion of Precision Medicine in Neurology

Precision medicine depends on accurate disease classification because therapeutic effectiveness varies according to underlying neuropathology. Pharmaceutical companies are increasingly developing targeted therapies that require validated diagnostic confirmation before treatment initiation. Healthcare institutions therefore require comprehensive diagnostic pathways capable of integrating biomarker analysis, neuroimaging, and clinical evaluation. Diagnostic manufacturers are expanding comprehensive testing portfolios that support personalized treatment selection, reinforcing sustained demand for advanced diagnostic technologies.

Market Restraints

High costs associated with advanced neuroimaging systems and specialized biomarker testing limit widespread adoption across resource-constrained healthcare settings. The limited availability of trained neurologists, neuroradiologists, and specialized laboratory professionals reduces diagnostic capacity despite increasing patient demand. Variability in reimbursement policies for emerging biomarker tests and advanced imaging procedures delays routine clinical adoption in several healthcare markets. Additionally, the complexity of integrating new diagnostic technologies with existing healthcare infrastructure presents operational hurdles. Data privacy and security concerns regarding patient health information create compliance burdens for diagnostic platform providers.

Technology and Segment Insights

By Product

Neuroimaging systems form the foundation of dementia diagnosis, providing structural and functional evidence that supports differentiation between neurodegenerative disorders. Hospitals are increasingly utilizing magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) to detect brain atrophy, vascular abnormalities, and amyloid or tau deposition. Blood-based biomarker tests are emerging as a transformative product category, simplifying diagnosis by reducing reliance on invasive lumbar puncture procedures. Cerebrospinal fluid biomarker tests remain important for patients requiring high diagnostic certainty, while genetic testing supports identification of hereditary dementia risk factors. Cognitive assessment tools and digital cognitive assessment platforms are gaining adoption as standardized evaluation methods across diverse healthcare settings.

By Diagnostic Technology

Magnetic resonance imaging serves as a cornerstone of dementia diagnosis, providing high-resolution visualization of structural brain abnormalities. Healthcare providers increasingly utilize advanced MRI techniques to identify hippocampal atrophy, cortical thinning, and white matter changes. Positron emission tomography enables detection of amyloid and tau deposition through specialized radiotracers, supporting earlier Alzheimer's disease identification. Biomarker diagnostics, including immunoassays for phosphorylated tau and amyloid-beta, are becoming essential for pathological confirmation. Molecular diagnostics provide genetic and proteomic insights that support disease classification. Artificial intelligence-based diagnostics are enhancing interpretation of neuroimaging and biomarker data, improving diagnostic consistency and workflow efficiency. Computed tomography remains valuable for excluding other neurological conditions and identifying vascular abnormalities.

By Dementia Type

Alzheimer's disease represents the largest segment of the dementia diagnostics market, accounting for the majority of dementia cases worldwide. Increasing requirements for biomarker confirmation before disease-modifying therapy initiation are strengthening demand for Alzheimer's diagnostics. Vascular dementia represents the second largest segment, driven by the prevalence of cerebrovascular disease in aging populations. Dementia with Lewy bodies, frontotemporal dementia, and mixed dementia each present distinct diagnostic challenges that require multimodal testing approaches. The availability of diagnostic technologies capable of differentiating between these dementia types is becoming increasingly important for clinical management.

Competitive and Strategic Outlook

The competitive landscape features a mix of global diagnostic conglomerates and specialized biotechnology companies. Roche Diagnostics distinguishes itself through its comprehensive precision diagnostics portfolio and strong focus on biomarker-driven neurological disease detection. The company has established a leading position by developing automated immunoassays for amyloid-beta and phosphorylated tau biomarkers on its Cobas analytical platforms. Fujirebio Holdings has established a strong competitive position through specialization in neurodegenerative disease biomarkers and automated immunoassay technologies, pioneering cerebrospinal fluid and blood-based biomarker assays. Siemens Healthineers differentiates itself through advanced medical imaging technologies, including MRI and PET systems, combined with artificial intelligence-enabled imaging software. GE HealthCare maintains a strong position through its broad portfolio of imaging solutions and digital healthcare technologies. Koninklijke Philips N.V. offers integrated diagnostic imaging and connected healthcare ecosystems supporting comprehensive neurological assessment. Beckman Coulter and Abbott Laboratories contribute through their expertise in clinical laboratory automation and immunoassay technologies.
Strategic developments include increasing collaborations between diagnostic manufacturers and pharmaceutical companies to develop companion diagnostics aligned with emerging Alzheimer's therapies. Companies are investing in multicenter clinical studies to validate blood-based biomarkers against cerebrospinal fluid analysis and amyloid PET imaging. Mergers and acquisitions are enabling diagnostic companies to broaden their technological portfolios and geographic reach. Product launches are focused on automated laboratory platforms, artificial intelligence-enabled imaging software, and integrated diagnostic workflows. Companies that successfully combine laboratory diagnostics, imaging technologies, and digital health platforms into unified clinical solutions are positioned to strengthen their long-term competitive positioning.

Conclusion

The dementia diagnostics market is poised for significant growth, driven by the transition toward pathology-based diagnosis and the increasing availability of disease-modifying therapies. Blood-based biomarkers, advanced neuroimaging, and artificial intelligence are becoming complementary technologies within integrated diagnostic pathways. Precision medicine is reshaping competitive strategies as therapeutic options require accurate patient stratification. Companies that successfully develop comprehensive diagnostic ecosystems, validate novel biomarkers, and establish strong regulatory and commercial capabilities will lead the market. The convergence of therapeutics, diagnostics, and digital health positions dementia diagnostics as an essential component of modern neurological care, with substantial opportunities for innovation and market expansion through 2035.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Dementia Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Dementia Disease Overview
3.3 Evolution of Dementia Diagnostics
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Classification
3.8 Epidemiology and Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Diagnostic Pathway and Clinical Workflow
3.11 Current Diagnostic Landscape and Unmet Clinical Needs

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Artificial Intelligence Integration
6.6 Digital Health Integration
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Dementia Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by Disease Stage

9. Global Dementia Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Neuroimaging Systems
- 9.1.2 Cerebrospinal Fluid (CSF) Biomarker Tests
- 9.1.3 Blood-Based Biomarker Tests
- 9.1.4 Genetic Testing
- 9.1.5 Cognitive Assessment Tools
- 9.1.6 Digital Cognitive Assessment Platforms
9.2 By Diagnostic Technology
- 9.2.1 Magnetic Resonance Imaging (MRI)
- 9.2.2 Computed Tomography (CT)
- 9.2.3 Positron Emission Tomography (PET)
- 9.2.4 Biomarker Diagnostics
- 9.2.5 Molecular Diagnostics
- 9.2.6 Artificial Intelligence-Based Diagnostics
9.3 By Dementia Type
- 9.3.1 Alzheimer's Disease
- 9.3.2 Vascular Dementia
- 9.3.3 Dementia with Lewy Bodies
- 9.3.4 Frontotemporal Dementia
- 9.3.5 Mixed Dementia
- 9.3.6 Other Dementias